Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,500

Employees2,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,500

Employees2,500

ALNY Key Statistics

Market cap

30.59B

Market cap30.59B

Price-Earnings ratio

37.92

Price-Earnings ratio37.92

Dividend yield

—

Dividend yield—

Average volume

1.73M

Average volume1.73M

High today

$230.91

High today$230.91

Low today

$222.01

Low today$222.01

Open price

$225.79

Open price$225.79

Volume

1.53M

Volume1.53M

52 Week high

$495.55

52 Week high$495.55

52 Week low

$197.81

52 Week low$197.81

Stock Snapshot

Alnylam Pharmaceuticals(ALNY) stock is priced at $228.61, giving the company a market capitalization of 30.59B. It carries a P/E multiple of 37.92.

On 2026-08-18, Alnylam Pharmaceuticals(ALNY) stock moved within a range of $222.01 to $230.91. With shares now at $228.61, the stock is trading +3.0% above its intraday low and -1.0% below the session's peak.

Trading volume for Alnylam Pharmaceuticals(ALNY) stock has reached 1.53M, versus its average volume of 1.73M.

The stock's 52-week range extends from a low of $197.81 to a high of $495.55.

ALNY News

TipRanks 5h

BMO Capital starts Alnylam at Outperform, sees attractive valuation

BMO Capital initiated coverage of Alnylam (ALNY) with an Outperform rating and $318 price target The company’s disappointing guidance during Q2 earnings piled o...

Nasdaq 3d

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing

Key Points Alnylam's stock has plunged due to a revenue guidance cut and other concerns. However, the full story for this biotech innovator is more positive t...

Simply Wall St 5d

Alnylam Pharmaceuticals Cuts Guidance As Undervalued Narrative Faces A Tougher Test

Alnylam Pharmaceuticals (ALNY) is under closer scrutiny after cutting its full-year 2026 TTR product sales guidance by about $200 million, which it linked to no...

Analyst ratings

78%

of 32 ratings

Buy

78.1%

Hold

21.9%

Sell

More ALNY News

Simply Wall St 7d

Is Alnylam’s Mixed 2026 Guidance Reset Altering The Investment Case For Alny?

In the second quarter of 2026, Alnylam Pharmaceuticals reported revenue of US$1,290.95 million and net income of US$164.49 million, a shift from a net loss a ye...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Vertex Pharmaceuticals

Salesforce

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.